Research on Compulsory Drug Patent Licensing in China Under Covid-19
Authors
Zhou Zhide, Yu Shanshan
Corresponding Author
Zhou Zhide
Available Online 28 August 2020.
- DOI
- 10.2991/assehr.k.200826.082How to use a DOI?
- Keywords
- covid-19, drug patents, the compulsory license, the applicant, licensing procedures
- Abstract
Covid-19 has spread in China and quickly spread to the world. The world health organization (WHO) has listed it as a public health emergency of international concern. In the face of this serious pandemic, global public security has been seriously threatened, and it is imperative to address the supply of medicines. This paper starts with the current situation of covid-19, compares the practice of compulsory drug patent licensing in different countries, and finds out the deficiency of compulsory drug patent licensing in China. Then put forward feasible suggestions for drug patent compulsory licensing.
- Copyright
- © 2020, the Authors. Published by Atlantis Press.
- Open Access
- This is an open access article distributed under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).
Cite this article
TY - CONF AU - Zhou Zhide AU - Yu Shanshan PY - 2020 DA - 2020/08/28 TI - Research on Compulsory Drug Patent Licensing in China Under Covid-19 BT - Proceedings of the 2020 4th International Seminar on Education, Management and Social Sciences (ISEMSS 2020) PB - Atlantis Press SP - 415 EP - 417 SN - 2352-5398 UR - https://doi.org/10.2991/assehr.k.200826.082 DO - 10.2991/assehr.k.200826.082 ID - Zhide2020 ER -